All In Biotech

Drug Trial Radar · NCT04844840

A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence

A Phase 2, Multi-Center, Randomized, Multiple Arm, Controlled Pilot Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Reducing Post- Keloidectomy Keloid Recurrence

Last checked: Nov 19, 2026Latest source record: Mar 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Apr 29, 2021

Primary completion

May 17, 2023

Study completion May 17, 2023

Sponsor

Lead sponsor
SirnaomicsIndustry
Sponsor type
Industry
First posted
Apr 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2, randomized, double-blind, multiple arm, controlled study to evaluate safety \& efficacy of various doses of STP705 in reducing post Keloidectomy keloid recurrence.

Conditions

  • Keloid

Interventions

  • STP705Drug

    STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively

  • PlaceboOther

    Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of RecurrenceTime frame: 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Investigate MD

    Scottsdale, Arizona

  • Center for Clinical and Cosmetic Research

    Aventura, Florida

  • Schweiger Dermatology

    Hackensack, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.